167412-23-9 Usage
General Description
N-(3,5-Difluorophenyl)hydrazinecarboxamide is a chemical compound with the molecular formula C7H7F2N3O. It is a derivative of hydrazine, containing a 3,5-difluorophenyl group. N-(3,5-DIFLUOROPHENYL)HYDRAZINECARBOXAMIDE is commonly used in medicinal chemistry research as a building block for the synthesis of biologically active compounds, particularly in the development of potential pharmaceuticals. It has been studied for its potential as an antitumor agent and in the treatment of certain neurological disorders. The chemical structure of N-(3,5-Difluorophenyl)hydrazinecarboxamide makes it an interesting candidate for further research and development in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 167412-23-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,7,4,1 and 2 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 167412-23:
(8*1)+(7*6)+(6*7)+(5*4)+(4*1)+(3*2)+(2*2)+(1*3)=129
129 % 10 = 9
So 167412-23-9 is a valid CAS Registry Number.
InChI:InChI=1/C7H7F2N3O/c8-4-1-5(9)3-6(2-4)12(11)7(10)13/h1-3H,11H2,(H2,10,13)
167412-23-9Relevant articles and documents
Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors
Qi, Baohui,Tao, Haiyan,Wu, Di,Bai, Jinying,Shi, Yandan,Gong, Ping
, p. 596 - 609 (2013/09/02)
Novel quinoline derivatives bearing acyclic semicarbazones were prepared and their chemical structures as well as the relative stereochemistry were confirmed. All the synthesized compounds were evaluated for their c-Met kinase inhibitory activity and their cytotoxicity against the cell lines HT-29, MKN-45, and MDA-MB-231 in vitro. Several potent compounds were further evaluated against A549 cells. Most compounds displayed moderate to excellent activity, and the structure-activity relationship studies identified the most promising compound 35 as a selective c-Met kinase inhibitor (IC50 = 4.3 nM). Compound 35 showed a 3.5- and 18.8-fold increase in cytotoxicity in vitro against HT-29 and A549 cells, respectively, compared to that of foretinib. Poor off-target effects of compound 35 were further confirmed by the antiproliferative activity against the c-Met inhibition less sensitive MDA-MB-231 cell line (IC50 = 0.77 μM). Copyright
